Abstract
Purpose: Prostate cancer is the most prevalent type of cancer in males in Brazil, with an increase of 29% new cases every year. Treatment may be done by surgery, radiotherapy or chemotherapy. Due to its size and diversity, the country has noticeable inequalities in the Unified Public Healthcare System (SUS). Therefore, we intend to analyze the time between malignant prostate cancer diagnosis and first treatment with possible disparities in this process in Brazil.
Methods: A cross-sectional design of data collected from the Oncology Panel of DATASUS’s Hospital Information System. The study analyzes the time between diagnosis and initial treatment for malignant prostate cancer between 2015 and 2020. There were 4 intervals: the same day, 1-30 days, 31-60 days, and above 60 days.
Results: The number of prostate treatments in Brazil, through the Public Health System (SUS), between January 2015 and December 2020, was 153.802. From those, 18.545 were performed the same day of diagnosis; 11.025 in the 1-30 days interval between diagnosis and treatment; 19.960 in the 31-60 days interval and 104.272 above 60 days. Hence, 49.530 (32,2%) treatments were performed within 60 days and 104.272 (67,8%) were performed after 60 days of diagnosis.
Conclusion: The Brazilian Law stipulates that the care must be provided within 60 days of diagnosis. However, the results of this study shows there is a significant delay in this system, which affects the morbimortality of the majority of patients subjected to postponements. As a result, it is essential to determine the extent of these consequences to improve the management and execution of malignant prostate cancer treatments.
Citation Format: Luiza Seixas de Sá Beltramo, Fernando Azambuja, Pedro Antonio Paludo Menna Barreto, Pedro Arthur Zimmer Silveira, Laura Tibola Marques da Silva, Lucas Kieling, Rafaela de Andrade, Arthur Minas Alberti, Gabriele Eckerdt Lech. Comparative Analysis of Time Between Diagnosis and First Treatment of Malignant Prostate Cancer in the Brazilian Public Health System (SUS) [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 23.